Recursion Pharmaceuticals

Recursion uses artificial intelligence to find new medicines for rare and serious diseases. They use computers to study millions of cell images and predict how drugs will work. This helps scientists discover potential treatments faster than traditional laboratory methods.

A High-Tech Drug Menu

• Oncology Pipeline: Targeted drug candidates designed to treat advanced solid tumors and certain types of blood cancer.
• Rare Disease Programs: Investigational medicines for genetic conditions like familial adenomatous polyposis, which leads to digestive system growths.
• Operating System: Digital platform integrating automated laboratories with machine learning to identify promising new drug leads.
• Strategic Collaborations: Joint research programs with major pharmaceutical companies to find new targets for neuroscience and immunology.

Growing the Discovery Engine

• Combined operations with Exscientia in 2025 to add automated chemical design to the discovery platform.
• Delivered whole-genome maps of human brain cells to Roche and Genentech, generating $213 million in cash to date.
• Prioritized the clinical portfolio in May 2025 to focus resources on the most promising cancer and rare disease treatments.
• Achieved a $4 million milestone payment from Sanofi in February 2026 for progress in small-molecule drug programs.

A New Way to Code

The company uses the BioHive-2 supercomputer to analyze millions of biological experiments conducted in its automated laboratories. This data allows bilingual teams of scientists and engineers to predict how different chemicals affect human biology.

Measuring the Money

• Revenue reached $35.5 million in Q4 2025, up 687.8% from Q4 2024.
• Gross profit hit $8.7 million in Q4 2025, up 204.6% from a loss in Q4 2024.
• Net loss reached $108.1 million in Q4 2025, narrowed 39.6% from the previous year.
• Free cash flow hit negative $47.3 million in Q4 2025, narrowed 59.6% from Q4 2024.

Bottom Line

Recursion has evolved from a digital concept into a clinical-stage business with several drugs in human testing. Its integrated technology platform aims to improve the efficiency and success rate of drug discovery at scale.